ACTRN12619001079134已完成1 期
A pilot study to increase the in vivo safety and infectivity of an in vitro expanded Plasmodium falciparum 3D7-MBE008 master cell bank in healthy subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Adult male and female (non-pregnant, non-lactating) subjects between 18 and 55 years of age inclusive, who do not live alone (from inoculation day until the end of the antimalarial treatment) and will be contactable and available for the duration of the trial and up to 2 weeks following the End of Study visit
- •2.Body weight minimum 50 kg, body mass index between 18 and 32 kg/m2, inclusive.
- •3.Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
- •4.Normal standard 12-lead ECG after 5 minutes resting in supine position.
- •5.Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects enrolled in this study.
排除标准
- •1.Any history of malaria or participation in a previous malaria challenge study.
- •2.Must not have travelled to or lived (>2 weeks) in a malaria-endemic region during the past 12 months or planned travel to a malaria-endemic region during the course of the study.
- •3.Has evidence of increased cardiovascular disease risk.
- •4.History of splenectomy.
- •5.Presence of acute infectious disease or fever (e.g., sublingual temperature greater than or equal to 38.5 degrees C) within the 5 days prior to inoculation with malaria parasites.
- •6.Evidence of acute illness within the 4 weeks prior to screening that the Investigator deems may compromise subject safety.
- •7.Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion, e.g. gastrectomy, diarrhoea.
- •8.Participation in any investigational product study within the 12 weeks preceding the study.
- •9.Blood donation of any volume within 1 month before inclusion, or participation in any research study involving blood sampling (more than 450 mL/unit of blood), or blood donation to a blood bank during the 8 weeks prior to the treatment drug dose in the study.
- •10.Subject who has ever received a blood transfusion.
- •11.Any vaccination within the last 28 days.
- •12.Any recent (less than 6 weeks) or current systemic therapy with an antibiotic or drug with potential antimalarial activity (i.e. chloroquine, piperaquine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, doxycycline etc.)
- •13.Cardiac/QT risk
- •14.Known hypersensitivity to artesunate or any of its excipients, artemether or other artemisinin derivatives, piperaquine, atovaquone/proguanil hydrochloride, primaquine, or 4-aminoquinolines.
- •15.Unwillingness to abstain from consumption of grapefruit or Seville oranges from inoculation day until end of antimalarial treatment
研究者
相似试验
招募中
1 期
A pilot study to characterize the safety and infectivity of a Plasmodium knowlesi parasite bank in healthy volunteersInfection - Other infectious diseasesMalariaACTRN12623001326684QIMR Berghofer Medical Research Institute4
已完成
1 期
A pilot study to characterise the in vivo safety and infectivity of a Plasmodium falciparum 3D7-GL master cell bank in healthy subjectsInfection - Other infectious diseasesMalariaACTRN12619001085167QIMR Berghofer Medical Research Institute2
进行中（未招募）
不适用
A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma, non resectableMedDRA version: 9.1Level: LLTClassification code 10033600Term: Pancreatic adenocarcinoma non-resectableEUCTR2006-005104-14-DEniversitätsklinikum Schleswig-Holstein20
已完成
不适用
Pilot experimental study for safety and efficacy of IND02 (standardized hydroalcoholic extract of Cinnamonum zeylanicum bark extract) in reducing symptoms of Seasonal Allergic Rhinitis.Seasonal Allergic RhinitisACTRN12618000030279Evidence Sciences Pty. Ltd.60
已完成
不适用
A pilot study to investigate safety and effectiveness of Collagen Matrix 10808 to increase soft tissue thickness simultaneous to GBR and implant placementK08.1Loss of teeth due to accident, extraction or local periodontal diseaseDRKS00006005Geistlich Pharma AG10